26 October 2026 ASX Announcement September 2026 Quarterly Activities Report • Government and regulatory approvals secured for the compassionate use of Galidesivir in patients infected in the Bundibugyo Ebola outbreak in Uganda • Real-world use of Galidesivir in Africa establishes an opportunity...
Quarterly Appendix 4C and Activities Report
Filed with ASX ·
6ix is reading this filing.
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- USAMRIID Marburg study advances towards dosing
- Galidesivir GMP manufacturing commences
- Pivotal Marburg data secured for Galidesivir FDA pathway
- Island boosts Galidesivir supply as Ebola surges
- Texas Biomed SOW accelerates pivotal FDA pathway
